IntelGenx to Present at the 18th Annual Rodman & Renshaw Global Investment Conference and the 11th Annual Singular Research
Conference
SAINT-LAURENT, CANADA--(Marketwired - Sept. 7, 2016) - IntelGenx Corp., (TSX VENTURE:IGX) (OTCQX:IGXT), today
announced that Dr. Horst Zerbe, President and Chief Executive Officer, will present at two upcoming conferences. Also
present and available for questions will be Andre Godin, Executive Vice-President and Chief Financial Officer.
Rodman & Renshaw 18th Annual Global Investment Conference
Date: Monday, September 12
Location: Lotte New York Palace Hotel, New York City
Presentation Time: 10:50 AM Eastern Time
11th Annual Singular Research Conference "Best of the Uncovereds"
Date: Thursday, September 22
Location: Luxe Sunset Boulevard Hotel, Los Angeles
About IntelGenx:
IntelGenx is a leading oral drug delivery company focused on the development and manufacturing of innovative pharmaceutical
oral films based on its proprietary VersaFilm™ technology platform. Established in 2003, the Montreal-based company is
listed on the TSX-V and OTC-QX.
IntelGenx highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D,
analytical method development, clinical monitoring, IP and regulatory services. IntelGenx state-of-the art manufacturing
facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production,
offering full service capabilities to our clients. More information is available about the company at: www.intelgenx.com.
Forward Looking Statements:
This document may contain forward-looking information about IntelGenx' operating results and business prospects that
involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the
meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as
amended. These statements include, but are not limited to, statements about IntelGenx' plans, objectives, expectations,
strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words
"may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions.
All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these
forward-looking statements are subject to a number of risks and uncertainties, IntelGenx' actual results could differ materially
from those expressed or implied by these forward looking statements. Factors that could cause or contribute to such differences
include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx' annual report on Form 10-K, filed
with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities and www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking
statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX
Venture Exchange), nor the OTCQX accepts responsibility for the adequacy or accuracy of this release.
Source: IntelGenx Technologies Corp.